Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RAUSERPIN vs ALDORIL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Rauwolfia alkaloid (reserpine) depletes catecholamines (norepinephrine, dopamine, serotonin) from sympathetic nerve endings and brain by irreversibly binding to vesicular monoamine transporter (VMAT). This results in reduced sympathetic outflow, decreased heart rate, and vasodilation.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Hypertension,Psychotic disorders (off-label),Schizophrenia (off-label)
Hypertension
Initial: 0.1-0.25 mg orally once daily; increase gradually to 0.5-1 mg per day in 2 divided doses. Maximum: 3 mg/day.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
Terminal elimination half-life: 4-8 hours; clinical context: requires multiple daily dosing to maintain therapeutic levels.
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Hepatic via CYP2D6; undergoes extensive first-pass metabolism; metabolites excreted in urine and feces.
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Primarily renal (60-70% as unchanged drug and metabolites); biliary/fecal (15-20%)
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
80-90% bound primarily to albumin
~90%, primarily to albumin
1.0-2.0 L/kg; clinical meaning: indicates extensive tissue distribution, including CNS.
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Oral: 80-90%; Intramuscular: 100%
Oral: 50–60% (extensive first-pass metabolism)
GFR 30-50 m L/min: reduce dose by 25%. GFR 15-29 m L/min: reduce dose by 50%. GFR <15 m L/min: avoid use.
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated.
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
Not approved for pediatric use; safety and efficacy not established.
Not recommended for pediatric use; safety in children under 12 years not established.
Initiate at 0.05 mg orally once daily; increase slowly. Maximum 1.5 mg/day. Monitor for orthostatic hypotension and sedation.
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
No FDA black box warning.
None
May cause severe depression with high risk of suicide,Electroconvulsive therapy (ECT) should be discontinued at least 7 days prior,Use cautiously in patients with history of peptic ulcer disease (increased gastric acid secretion),May precipitate biliary colic in patients with gallstones,Monitor for hypotension and bradycardia
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
Hypersensitivity to rauwolfia alkaloids,History of mental depression (especially suicidal ideation),Active peptic ulcer,Ulcerative colitis,Electroconvulsive therapy (within 7 days),Pheochromocytoma,Concomitant use with MAO inhibitors
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
Avoid high-tyramine foods (e.g., aged cheeses, cured meats, pickled fish, ferments) as RAUSERPIN may potentiate their pressor effects, leading to hypertensive crisis. Limit alcohol intake due to increased risk of hypotension and sedation.
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
Rauserpin (reserpine) crosses the placenta. First trimester: Increased risk of congenital malformations including skeletal and cardiovascular anomalies based on animal studies; human data limited but avoid use. Second and third trimesters: Fetal bradycardia, hypothermia, and respiratory depression due to catecholamine depletion. Neonatal withdrawal: Lethargy, nasal congestion, and poor feeding. Avoid use throughout pregnancy.
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
Reserpine is excreted into breast milk with an M/P ratio of approximately 1.0. Potential for significant effects in the nursing infant including bradycardia, sedation, and gastrointestinal disturbances. Use is contraindicated during breastfeeding.
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
Plasma volume expansion in pregnancy may reduce reserpine concentrations. No established dose adjustment guidelines; clinical response monitoring is recommended. Avoid due to fetal risks. If unavoidable, use lowest effective dose and frequent monitoring.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
RAUSERPIN (rauwolfia alkaloid) is an antihypertensive that depletes catecholamines from postganglionic sympathetic nerve endings. Onset of effect is slow (weeks), and it may cause significant bradycardia and sedation. Avoid in patients with history of depression, peptic ulcer disease, or pheochromocytoma. Use with caution in patients receiving MAOIs or other antihypertensives due to additive effects.
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
Take this medication exactly as prescribed, usually once daily at the same time each day.,It may take several weeks to see the full benefit; do not stop abruptly as this may cause rapid increase in blood pressure.,This drug may cause drowsiness, dizziness, or nasal congestion; avoid driving or operating machinery until you know how it affects you.,Avoid alcohol and sedatives as they may worsen drowsiness.,Contact your doctor if you experience depression, slow heart rate, fainting, or signs of stomach ulcer (e.g., black stools, stomach pain).
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RAUSERPIN vs ALDORIL 15, answered by our medical review team.
RAUSERPIN is a Antihypertensive that works by Rauwolfia alkaloid (reserpine) depletes catecholamines (norepinephrine, dopamine, serotonin) from sympathetic nerve endings and brain by irreversibly binding to vesicular monoamine transporter (VMAT). This results in reduced sympathetic outflow, decreased heart rate, and vasodilation.. ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RAUSERPIN and ALDORIL 15 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RAUSERPIN is: Initial: 0.1-0.25 mg orally once daily; increase gradually to 0.5-1 mg per day in 2 divided doses. Maximum: 3 mg/day.. The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RAUSERPIN and ALDORIL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RAUSERPIN is classified as Category C. Rauserpin (reserpine) crosses the placenta. First trimester: Increased risk of congenital malformations including skeletal and cardiovascular anomalies based on animal studies; hum. ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.